Business Wire

FANUC Uses Mindbreeze for Proactive Knowledge Management

8.4.2025 15:02:00 CEST | Business Wire | Press Release

Share

FANUC Europe Corporation chooses Mindbreeze InSpire for intelligent information provision for customers, partners and employees. By integrating the AI-based knowledge management solution into the FANUC service portal, users of the FANUC service portal will receive a new experience when searching for information.

With Mindbreeze, FANUC is replacing the current solution and taking its service portal to a new level. Customers and partners benefit from the possibilities of proactive knowledge management through integration into the FANUC website. The portal is also available to employees as a workplace integration directly in their preferred program.

“In our new ‘MyFANUC’, product-related information is now perfectly prepared and made available accordingly. We can now implement this project efficiently with Mindbreeze as our partner,” explains Rolf Urban, Head of Service Sales Coordination Europe.

As an additive system, FANUC has integrated Mindbreeze InSpire knowledge management solution into its existing IT landscape via the provided connectors. Access rights are always queried directly at the connected data sources, so that even short-term changes are considered. In addition to an intuitive user interface, the launch also provides portal visitors with AI-based functionalities such as chatting with documents or creating summaries.

Daniel Fallmann, founder and CEO of Mindbreeze, adds: “We are particularly pleased about the collaboration with FANUC and how the use of AI-based solutions can offer immediately visible added value for customers, partners, and employees.”

About FANUC

FANUC Europe Corporation is the European subsidiary of the Japanese FANUC Corporation, a world leader in factory automation. From its headquarters in Echternach/Luxembourg, it provides centralized support to the 24 European FANUC subsidiaries in the areas of sales and service, product support, supply chain, spare parts and repairs, marketing, human resources, IT, and administration. In total, FANUC Europe Corporation employs around 1800 people at various locations in Europe, of which around 300 work at the headquarters in Echternach.

About Mindbreeze

Mindbreeze is a global leader in AI-powered enterprise intelligence, with headquarters in Europe and the US. Mindbreeze InSpire redefines how organizations access and utilize information. Powered by advanced AI, it transforms complex data into actionable insights, seamlessly connecting and analyzing information across systems.

Unlike traditional solutions, our AI agents deliver hyper-relevant, context-aware insights tailored to unique business needs, enabling smarter, faster decision-making. With unmatched integration capabilities, data security, and automation at its core, Mindbreeze InSpire maximizes the value of your information ecosystem while driving innovation.

Trusted by industry leaders and recognized for our cutting-edge technology, Mindbreeze leads the way in unlocking new dimensions of enterprise intelligence.

Learn more at www.mindbreeze.com or follow us on LinkedIn and X @Mindbreeze.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408723224/en/

Contacts

Ulrike Kogler
+43 732 606162 620
pr@mindbreeze.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye